Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Лечение симптомов нижних мочевых путей у пациентов с доброкачественной гиперплазией предстательной железы: современные международные стандарты - Справочник поликлинического врача №10 (2015)
Лечение симптомов нижних мочевых путей у пациентов с доброкачественной гиперплазией предстательной железы: современные международные стандарты
П.И.Раснер, Д.Ю.Пушкарь. Лечение симптомов нижних мочевых путей у пациентов с доброкачественной гиперплазией предстательной железы: современные международные стандарты. Справочник поликлинического врача. 2015; 10: 20–26.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Athanasopoulos A. The Role of Antimuscarinics in the Management of Men With Symptoms of Overactive Bladder Associated With Concomitant Bladder Outlet Obstruction: An Update. Eur Urol 2011. http://www.doi:10.1016/j.eururo.2011.03.054
2. Hutchison A, Farmer R, Verhamme K et al. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 2007; 51: 207–16.
3. Brown CT, Yap T, Cromwell DA et al. Self-management for men with lower urinary tract symptoms – a randomised controlled trial. BMJ 2007; 334 (7583): 25.
4. McConnell JD. For the MTOPS Research Group. The long term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Eng J Med 2003; 349: 2385–96.
5. Jacobsen SJ, Jacobson DJ, Girman CJ et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158 (2): 481–9.
6. Isaacs JT. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate 1990; 3 (Suppl.): 1–7.
7. Flanigan RC, Reda DJ, Wasson JH et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic BPH: a Department of Veterans Affairs cooperative study. J Urol 1998; 160 (1): 12–6.
8. Gravas S (chair), Bachmann A, Descazeaud A et al. Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). http://www.uroweb.org/gls/pdf/Non-Neurogenic%20Male%20LUTS_(2705).pdf
9. Djavan B, Chapple C, Milani S et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004; 64 (6): 1081–8.
10. Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5a-reductase inhibitors for the enlarged prostate. Clin Ther 2007; 29 (1): 17–25.
11. Roehrborn CG, Boyle P, Nickel JC et al. ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60 (3): 434–41.
12. Sairam K, Kulinskaya E, Mc-Nicholas TA et al. Sildenafil influences LUTS. Brit J Urol Int 2002; 90 (7): 836–9.
13. Uckert S, Oelke М. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Brit J Clin Pharmacol 2011; 72 (2): 197–204.
14. Roehrborn CG, McVary KT, Elion-Mboussa A et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180 (4): 1228–34.
15. Porst H, McVary KT, Montorsi F et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and sign and symptoms of benign prostatic hyperplasia. Eur Urol 2009; 56 (4): 727–35.
16. Kaplan Steven A. Medical Therapy for Benign Prostatic Hyperplasia: New Terminology, New Concepts, Better Choices. Rev Urol 2006; 8 (1): 14–22.
17. Witte LP, Mulder WM, De la Rosette JJ et al. Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? Curr Opin Urol 2009; 19 (1): 13–9.
18. Roehrborn CG, Siami P, Barkin J et al. CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57 (1): 123–31.
19. Kaplan SA, Roehrborn CG, Rovner ES et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA 2006; 296 (19): 2319–28.
20. Mamoulakis C, Trompetter M, De la Rosette J. Bipolar transurethral resection of the prostate: the ‘golden standard’ reclaims its leading position. Curr Opin Urol 2009; 19 (1): 26–32.
21. Gilling PJ, Aho TF, Frampton CF et al. Holmium laser enucleation of the prostate: results at 6 years. Eur Urol 2008; 53 (4): 744–9.
22. Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol 2008; 53 (1): 160–6.
23. Mattiasson A, Abrams P, Van Kerrebroeck P et al. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 2002; 89 (9): 855–62.
24. Yu X, Elliott SP, Wilt TJ et al. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. J Urol 2008; 180 (1): 241–5.
2. Hutchison A, Farmer R, Verhamme K et al. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 2007; 51: 207–16.
3. Brown CT, Yap T, Cromwell DA et al. Self-management for men with lower urinary tract symptoms – a randomised controlled trial. BMJ 2007; 334 (7583): 25.
4. McConnell JD. For the MTOPS Research Group. The long term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Eng J Med 2003; 349: 2385–96.
5. Jacobsen SJ, Jacobson DJ, Girman CJ et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158 (2): 481–9.
6. Isaacs JT. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate 1990; 3 (Suppl.): 1–7.
7. Flanigan RC, Reda DJ, Wasson JH et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic BPH: a Department of Veterans Affairs cooperative study. J Urol 1998; 160 (1): 12–6.
8. Gravas S (chair), Bachmann A, Descazeaud A et al. Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). http://www.uroweb.org/gls/pdf/Non-Neurogenic%20Male%20LUTS_(2705).pdf
9. Djavan B, Chapple C, Milani S et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004; 64 (6): 1081–8.
10. Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5a-reductase inhibitors for the enlarged prostate. Clin Ther 2007; 29 (1): 17–25.
11. Roehrborn CG, Boyle P, Nickel JC et al. ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60 (3): 434–41.
12. Sairam K, Kulinskaya E, Mc-Nicholas TA et al. Sildenafil influences LUTS. Brit J Urol Int 2002; 90 (7): 836–9.
13. Uckert S, Oelke М. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Brit J Clin Pharmacol 2011; 72 (2): 197–204.
14. Roehrborn CG, McVary KT, Elion-Mboussa A et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180 (4): 1228–34.
15. Porst H, McVary KT, Montorsi F et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and sign and symptoms of benign prostatic hyperplasia. Eur Urol 2009; 56 (4): 727–35.
16. Kaplan Steven A. Medical Therapy for Benign Prostatic Hyperplasia: New Terminology, New Concepts, Better Choices. Rev Urol 2006; 8 (1): 14–22.
17. Witte LP, Mulder WM, De la Rosette JJ et al. Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? Curr Opin Urol 2009; 19 (1): 13–9.
18. Roehrborn CG, Siami P, Barkin J et al. CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57 (1): 123–31.
19. Kaplan SA, Roehrborn CG, Rovner ES et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA 2006; 296 (19): 2319–28.
20. Mamoulakis C, Trompetter M, De la Rosette J. Bipolar transurethral resection of the prostate: the ‘golden standard’ reclaims its leading position. Curr Opin Urol 2009; 19 (1): 26–32.
21. Gilling PJ, Aho TF, Frampton CF et al. Holmium laser enucleation of the prostate: results at 6 years. Eur Urol 2008; 53 (4): 744–9.
22. Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol 2008; 53 (1): 160–6.
23. Mattiasson A, Abrams P, Van Kerrebroeck P et al. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 2002; 89 (9): 855–62.
24. Yu X, Elliott SP, Wilt TJ et al. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. J Urol 2008; 180 (1): 241–5.
Авторы
П.И.Раснер, Д.Ю.Пушкарь
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.